A French single-center experience on allogeneic stem cell transplant cryopreservation during severe acute respiratory syndrome coronavirus 2 pandemic
暂无分享,去创建一个
N. Thilly | D. Bensoussan | A. Luc | M. Rubio | C. Pochon | C. Laroye | V. Decot | V. Latger‐Cannard | V. Eschwège | M. Gauthier | A. Campidelli | M. D’Aveni
[1] Xiao-hui Zhang,et al. Hematopoietic Stem Cell Transplantation Activity in China 2020–2021 During the SARS-CoV-2 Pandemic: A Report From the Chinese Blood and Marrow Transplantation Registry Group , 2022, Transplantation and Cellular Therapy.
[2] Y. Kanda,et al. Cryopreservation of Unrelated Hematopoietic Stem Cells from a Blood and Marrow Donor Bank During the COVID-19 Pandemic: A Nationwide Survey by the Japan Marrow Donor Program , 2021, Transplantation and Cellular Therapy.
[3] D. Benhamou,et al. ICU bed capacity during COVID-19 pandemic in France: From ephemeral beds to continuous and permanent adaptation , 2021, Anaesthesia Critical Care & Pain Medicine.
[4] S. Devine,et al. Meeting the Demand for Unrelated Donors in the Midst of the COVID-19 Pandemic: Rapid Adaptations by the National Marrow Donor Program and Its Network Partners Ensured a Safe Supply of Donor Products , 2020, Transplantation and Cellular Therapy.
[5] P. Chiusolo,et al. Coronavirus disease 2019 pandemic and allogeneic hematopoietic stem cell transplantation: a single center reappraisal , 2020, Cytotherapy.
[6] I. Schmale. European Society for Blood and Marrow Transplantation , 2020, Onkologische Welt.
[7] D. Curtis,et al. Variable CD34+ recovery of cryopreserved allogeneic HPC products: transplant implications during the COVID-19 pandemic , 2020, Blood advances.
[8] S. Montoto,et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy , 2020, Bone Marrow Transplantation.
[9] C. Quinto,et al. Coronavirus Disease 2019 , 2020, Clinics in Geriatric Medicine.
[10] J. Szer,et al. The impact of COVID-19 on the provision of donor hematopoietic stem cell products worldwide: collateral damage , 2020, Bone Marrow Transplantation.
[11] Le Chang,et al. Coronavirus Disease 2019: Coronaviruses and Blood Safety , 2020, Transfusion Medicine Reviews.
[12] A. Chanan-Khan,et al. Autologous Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel Therapies. , 2020, JCO oncology practice.
[13] J. Oldenburg,et al. Variable resistance to freezing and thawing of CD34-positive stem cells and lymphocyte subpopulations in leukapheresis products. , 2016, Cytotherapy.
[14] H. Greinix,et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .
[15] J. Ferrara,et al. Advances in predicting acute GVHD , 2013, British journal of haematology.
[16] D. Paniagua,et al. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] F. Massin,et al. Validation of a single-platform method for hematopoietic CD34+ stem cells enumeration according to accreditation procedure. , 2015, Bio-medical materials and engineering.
[18] J. Stoltz,et al. Thawed autologous peripheral blood stem cells require modified quantification methods for hematopoietic progenitor cell evaluation. , 2012, Bio-medical materials and engineering.
[19] F. Appelbaum,et al. Successful engraftment of cryopreserved autologous bone marrow in patients with malignant lymphoma. , 1978, Blood.